These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 29720872)

  • 1. Adherence to subcutaneous interferon beta-1a treatment using an electronic injection device: a prospective open-label Scandinavian noninterventional study (the ScanSmart study).
    Pedersen ED; Stenager E; Vadgaard JL; Jensen MB; Schmid R; Meland N; Magnussen G; Frederiksen JL
    Patient Prefer Adherence; 2018; 12():569-575. PubMed ID: 29720872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient adherence to and tolerability of self-administered interferon β-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study.
    Lugaresi A; Florio C; Brescia-Morra V; Cottone S; Bellantonio P; Clerico M; Centonze D; Uccelli A; di Ioia M; De Luca G; Marcellusi A; Paolillo A;
    BMC Neurol; 2012 Mar; 12():7. PubMed ID: 22390218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term adherence of patients with relapsing-remitting multiple sclerosis to subcutaneous self-injections of interferon β-1a using an electronic device: the RIVER study.
    Lugaresi A; De Robertis F; Clerico M; Brescia Morra V; Centonze D; Borghesan S; Maniscalco GT;
    Expert Opin Drug Deliv; 2016 Jul; 13(7):931-5. PubMed ID: 26909646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb study.
    Devonshire V; Arbizu T; Borre B; Lang M; Lugaresi A; Singer B; Verdun di Cantogno E; Cornelisse P
    BMC Neurol; 2010 Apr; 10():28. PubMed ID: 20433746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Term Adherence to IFN Beta-1a Treatment when Using RebiSmart® Device in Patients with Relapsing-Remitting Multiple Sclerosis.
    Fernández O; Arroyo R; Martínez-Yélamos S; Marco M; Merino JA; Muñoz D; Merino E; Roque A;
    PLoS One; 2016; 11(8):e0160313. PubMed ID: 27526201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adherence to, and effectiveness of, subcutaneous interferon β-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: results of the 1-year, observational SMART study.
    Bayas A; Ouallet JC; Kallmann B; Hupperts R; Fulda U; Marhardt K;
    Expert Opin Drug Deliv; 2015 Aug; 12(8):1239-50. PubMed ID: 26098143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subjective patient-reported versus objective adherence to subcutaneous interferon β-1a in multiple sclerosis using RebiSmart®: the CORE study.
    Zecca C; Disanto G; Mühl S; Gobbi C
    BMC Neurol; 2017 Sep; 17(1):171. PubMed ID: 28870152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subcutaneous Interferon β-1a Administration by Electronic Auto-injector is Associated with High Adherence in Patients with Relapsing Remitting Multiple Sclerosis in a Real-life Study.
    Järvinen E; Multanen J; Atula S
    Neurol Int; 2017 Feb; 9(1):6957. PubMed ID: 28286627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adherence to Subcutaneous Interferon Beta-1a in Multiple Sclerosis Patients Receiving Periodic Feedback on Drug Use by Discussion of Readouts of Their Rebismart
    Rieckmann P; Ziemssen T; Penner IK; Raji A; Wagner T; Richter J; Zettl UK
    Adv Ther; 2022 Jun; 39(6):2749-2760. PubMed ID: 35428903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-rated ease of use and functional reliability of an electronic autoinjector for self-injection of subcutaneous interferon beta-1a for relapsing multiple sclerosis.
    Singer B; Wray S; Miller T; Cascione M; Gupta A; Pardo G; Watsky E; Hayward B; Mercer B; Dangond F
    Mult Scler Relat Disord; 2012 Apr; 1(2):87-94. PubMed ID: 25876936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adherence to Subcutaneous IFN β-1a in Multiple Sclerosis: Final Analysis of the Non-Interventional Study READOUTsmart Using the Dosing Log and Readout Function of RebiSmart
    Rieckmann P; Schwab M; Pöhlau D; Penner IK; Wagner T; Schel E; Bayas A
    Adv Ther; 2019 Jan; 36(1):175-186. PubMed ID: 30488338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adherence to interferon β-1a therapy using an electronic self-injector in multiple sclerosis: a multicentre, single-arm, observational, phase IV study.
    Devonshire VA; Feinstein A; Moriarty P
    BMC Res Notes; 2016 Mar; 9():148. PubMed ID: 26951043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An observational, retrospective, UK and Ireland audit of patient adherence to subcutaneous interferon beta-1a injections using the RebiSmart(®) injection device.
    Willis H; Webster J; Larkin AM; Parkes L
    Patient Prefer Adherence; 2014; 8():843-51. PubMed ID: 24966669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adherence to self-administering interferon-β1a using RebiSmart® device in Mexican patients with relapsing multiple sclerosis.
    Sauri-Suárez S; Quiñones-Aguilar S; Contreras-Marín A; Ramiro-Guerrero EO; Zúñiga-García D; Salinas-Vázquez L; Llamas-López L; León-Jiménez C; García-Martell A; González-Hernández I; Chiquete E; García S
    PLoS One; 2020; 15(4):e0230959. PubMed ID: 32310950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The STAR Study: a real-world, international, observational study of the safety and tolerability of, and adherence to, serum-free subcutaneous interferon β-1a in patients with relapsing multiple sclerosis.
    Hupperts R; Ghazi-Visser L; Martins Silva A; Arvanitis M; Kuusisto H; Marhardt K; Vlaikidis N;
    Clin Ther; 2014 Dec; 36(12):1946-1957. PubMed ID: 24811754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicenter Interventional Phase IV Study for the Assessment of the Effects on Patient's Satisfaction of Peg IFN Beta-1a (Pre-filled Pen) in Subjects With Relapsing-Remitting Multiple Sclerosis Unsatisfied With Other Injectable Subcutaneous Interferons (PLATINUM Study).
    Centonze D; Fantozzi R; Buttari F; Grimaldi LME; Totaro R; Corea F; Marrosu MG; Confalonieri P; Cottone S; Trojano M; Zipoli V
    Front Neurol; 2021; 12():637615. PubMed ID: 33967938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Seasonal adherence to, and effectiveness of, subcutaneous interferon β-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: results of the 1-year, observational GEPAT-SMART study.
    Deftereos SN; Koutlas E; Koutsouraki E; Kyritsis A; Papathanassopoulos P; Fakas N; Tsimourtou V; Vlaikidis N; Tavernarakis A; Voumvourakis K; Arvanitis M; Sakellariou D; DeLorenzo F
    BMC Neurol; 2018 Nov; 18(1):186. PubMed ID: 30400884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient assessment of an electronic device for subcutaneous self-injection of interferon β-1a for multiple sclerosis: an observational study in the UK and Ireland.
    D'Arcy C; Thomas D; Stoneman D; Parkes L
    Patient Prefer Adherence; 2012; 6():55-61. PubMed ID: 22298944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative injection-site pain and tolerability of subcutaneous serum-free formulation of interferonβ-1a versus subcutaneous interferonβ-1b: results of the randomized, multicenter, Phase IIIb REFORMS study.
    Singer B; Bandari D; Cascione M; LaGanke C; Huddlestone J; Bennett R; Dangond F;
    BMC Neurol; 2012 Dec; 12():154. PubMed ID: 23216674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of adherence on subcutaneous interferon beta-1a effectiveness administered by Rebismart
    Edo Solsona MD; Monte Boquet E; Casanova Estruch B; Poveda Andrés JL
    Patient Prefer Adherence; 2017; 11():415-421. PubMed ID: 28280313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.